Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 49.05
+0.35 (0.72%)
At close: Nov 28, 2025
Basilea Pharmaceutica AG Employees
Basilea Pharmaceutica AG had 164 employees as of December 31, 2024. The number of employees increased by 17 or 11.56% compared to the previous year.
Employees
164
Change (1Y)
17
Growth (1Y)
11.56%
Revenue / Employee
1.31M CHF
Profits / Employee
403.66K CHF
Market Cap
602.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164 | 17 | 11.56% |
| Dec 31, 2023 | 147 | 6 | 4.26% |
| Dec 31, 2022 | 141 | -13 | -8.44% |
| Dec 31, 2021 | 154 | -3 | -1.91% |
| Dec 31, 2020 | 157 | -68 | -30.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Novartis AG | 75,883 |
| Alcon | 25,599 |
| Sandoz Group AG | 22,049 |
| Lonza Group AG | 18,944 |
| Sonova Holding AG | 18,366 |
| Straumann Holding AG | 11,815 |
| Galenica AG | 7,971 |
Basilea Pharmaceutica AG News
- 26 days ago - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea - GlobeNewsWire
- 2 months ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire
- 2 months ago - Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 - GlobeNewsWire
- 3 months ago - Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - Basilea Pharmaceutica AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Basilea Pharmaceutica AG GAAP EPS of CHF 1.26, revenue of CHF 104M; updates FY outlook - Seeking Alpha
- 3 months ago - Basilea on track with strong 2025 half-year results - GlobeNewsWire
- 3 months ago - Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic - GlobeNewsWire